Prostate Clinical Trials 2024

What are the top hospitals conducting prostate research?

When it comes to innovative clinical trials in prostate cancer, several top hospitals are making remarkable strides. At Memorial Sloan Kettering Cancer Center in New york, five active prostate trials are currently underway, with a noteworthy history of two previously conducted studies dating back to their first trial in 1990. Mayo Clinic in Scottsdale, Arizona may not have any completed prostate trials on record yet but is actively engaged in four ongoing research projects focused on this condition. In Los Angeles, Cedars-Sinai Medical Center has contributed significantly to the field with three active prostate trials and a total of two completed studies since their inaugural trial was recorded in 2008.

Meanwhile, at the University of California, San Francisco (UCSF), groundbreaking research is taking place as they conduct three current clinical trials for prostate cancer. Although UCSF does not have any prior completed prostate trials documented thus far, their commitment to pushing boundaries and exploring new avenues remains unwavering.

These esteemed institutions serve as beacons of hope for patients diagnosed with or concerned about prostate cancer. Their dedication to advancing medical knowledge through clinical trials underscores the importance of collaborative efforts within the healthcare community. By continuously pushing boundaries and seeking breakthroughs through these endeavors, these hospitals are working diligently towards improved treatment options and outcomes for individuals affected by this prevalent disease

Which are the best cities for prostate clinical trials?

When it comes to prostate clinical trials, several cities are at the forefront of research and development. New york, with its 24 ongoing trials, explores treatments like Docetaxel and CC-94676. Toronto follows closely behind with 19 active studies focusing on Metformin, Docetaxel, Durvalumab and Tremelimumab. Baltimore also plays a significant role with 16 trials studying interventions such as Docetaxel and P-PSMA-101 CAR-T cells. These cities offer individuals battling prostate cancer access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs.

Which are the top treatments for prostate being explored in clinical trials?

Exciting advancements are underway in the field of prostate cancer treatment, with clinical trials exploring various options. One standout treatment on the horizon is the 177Lu-rhPSMA-10.1 injection. Although it is currently being tested in just one active trial, this innovative therapy has already shown promise for prostate cancer patients. First listed in 2022, its potential to revolutionize treatment approaches makes it a treatment worth keeping an eye on as researchers continue their dedicated efforts to combat this disease.

What are the most recent clinical trials for prostate?

Recent clinical trials present promising advancements in the field of prostate cancer research, offering hope for improved treatment options. Notably, a phase 1 and phase 2 trial has explored the potential benefits of Dose Level 1: 40mg for prostate patients. Additionally, another study investigated the effectiveness of a fasting mimicking diet as an adjunct therapy for prostate cancer in a phase 2 trial. Another noteworthy trial focuses on an extended course of Sipuleucel-T treatment to evaluate its impact on disease progression. Furthermore, researchers have delved into RARP + IS-002 + intraoperative near-infrared imaging as a potential approach for treating prostate cancer during a phase 2 trial. Lastly, rhPSMA-7.3 is being evaluated in a phase 3 trial with hopes of establishing its efficacy as targeted therapy for advanced-stage prostate cancer patients. These groundbreaking studies highlight progress within the field and offer optimism for individuals affected by this disease.

What prostate clinical trials were recently completed?

Several recent clinical trials focused on prostate cancer have achieved important milestones, bringing advancements in treatment closer to reality. Notably, a trial investigating the efficacy of Enzalutamide was completed in November 2021. Similarly, another study exploring the potential of Abiraterone acetate reached completion in October 2021. Additionally, a trial evaluating the effectiveness of Apalutamide wrapped up earlier this year in January 2021. These significant developments demonstrate ongoing efforts by researchers to improve outcomes for patients with prostate cancer and offer hope for better therapeutic options moving forward.